pembrolizumab
merck
['melanoma', 'pembro']
adjuvant pembrolizumab after resected stage iii #melanoma led to a 5-year recurrence-free survival of 55.4%, compared with 38.3% in pts treated with placebo. #esmo22 
NEJM Evidence, a new journal from NEJM Group, presents innovative #OriginalResearch and fresh, bold ideas in #ClinicalTrial design and clinical decision-making.